Humana Inc. $HUM Shares Bought by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. grew its stake in shares of Humana Inc. (NYSE:HUM) by 10.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 955 shares of the insurance provider’s stock after acquiring an additional 89 shares during the period. Atria Wealth Solutions Inc.’s holdings in Humana were worth $234,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Cary Street Partners Investment Advisory LLC increased its stake in shares of Humana by 63.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock worth $31,000 after purchasing an additional 46 shares in the last quarter. Applied Finance Capital Management LLC increased its stake in shares of Humana by 1.7% during the 1st quarter. Applied Finance Capital Management LLC now owns 2,943 shares of the insurance provider’s stock worth $779,000 after purchasing an additional 48 shares in the last quarter. Blue Trust Inc. increased its stake in shares of Humana by 3.6% during the 2nd quarter. Blue Trust Inc. now owns 1,367 shares of the insurance provider’s stock worth $334,000 after purchasing an additional 48 shares in the last quarter. Achmea Investment Management B.V. grew its stake in Humana by 0.5% in the 1st quarter. Achmea Investment Management B.V. now owns 10,379 shares of the insurance provider’s stock worth $2,746,000 after acquiring an additional 49 shares during the period. Finally, Beech Hill Advisors Inc. grew its stake in Humana by 6.1% in the 1st quarter. Beech Hill Advisors Inc. now owns 865 shares of the insurance provider’s stock worth $229,000 after acquiring an additional 50 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Performance

NYSE:HUM opened at $287.97 on Thursday. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $34.63 billion, a price-to-earnings ratio of 22.10, a PEG ratio of 1.73 and a beta of 0.42. The firm’s fifty day simple moving average is $281.38 and its 200 day simple moving average is $258.81. Humana Inc. has a twelve month low of $206.87 and a twelve month high of $315.35.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%.The firm had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. During the same quarter in the prior year, the firm earned $6.96 EPS. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, equities research analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Friday, September 26th. Humana’s dividend payout ratio is 27.17%.

Wall Street Analysts Forecast Growth

HUM has been the subject of several recent analyst reports. Robert W. Baird lowered their target price on shares of Humana from $300.00 to $297.00 and set a “neutral” rating for the company in a research note on Friday, July 25th. Barclays lowered their target price on shares of Humana from $315.00 to $245.00 and set an “equal weight” rating for the company in a research note on Friday, October 3rd. Royal Bank Of Canada lifted their target price on shares of Humana from $283.00 to $322.00 and gave the stock an “outperform” rating in a research note on Thursday, August 21st. Wells Fargo & Company lifted their target price on shares of Humana from $344.00 to $347.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 7th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Humana in a research note on Friday, October 3rd. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $297.58.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.